In 2018, Rubraca launched a maintenance indication for BRCAmut+ and BRCAwt women with recurrent ovarian cancer. The Patient
Profile detail aid was created to help establish Rubraca as the PARPi
of choice for all comers by delivering clinical differentiation across a broad range of patient types, while also personifying the types of patients Rubraca is approved for use for. Designed tabbed 12 page brochure, with trifold flap for ISI.